Benzinga · Feb 6, 2026
LY
NASDAQ · LYRA
Lyra Therapeutics, Inc.
Healthcare · Biotechnology
$0.19
Up+$0.00 (+0.00%)
Updated Oct 10, 2026, 10:04 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.96M
- P/E ratio
- -0.14
- Dividend yield
- 0.00%
- 52-week range
- $0.31 – $37.50
- Volume
- 1.66K
- Avg. volume
- 54.82K
Price performance · LYRA
LYRA price history
1M range · 0 trading sessions · Daily adjusted prices
LYRA does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest LYRA news
The latest Smart Investors Daily articles mentioning LYRA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LYRA research
Overview
Company profile and research snapshot.
Company profile
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $0.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2025 | HC Wainwright & Co. | Neutral | — |
| Jun 10, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 14, 2025 | HC Wainwright & Co. | Neutral | — |
| Aug 15, 2024 | HC Wainwright & Co. | Neutral | — |
| Aug 15, 2024 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 6, 2026
Lyra Therapeutics Receives Nasdaq Delisting Notification
SEC
Benzinga · Jan 28, 2026
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · Jan 28, 2026
12 Health Care Stocks Moving In Wednesday's Intraday Session
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
